Catalog No.
PHD12601
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human VEGFA (Ala27-Arg232).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Vascular endothelial growth factor A,VPF,VEGFA,VEGF,Vascular permeability factor,VEGF-A
Purification
Purified by antigen affinity column.
Accession
P15692
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Advances in Molecular Imaging of VEGFRs: Innovations in Imaging and Therapeutics., PMID:40508182
Monoclonal Antibodies Against Vascular Endothelial Growth Factor A (VEGF-A) Reduce Synovitis, Bone Damage, and Osteogenesis in an SKG Mouse Model of Spondyloarthritis., PMID:40487799
Clinical characteristics and treatment response of treatment requiring retinopathy of prematurity (ROP) in Big Premature Infants in Turkiye: BIG-ROP Study Group Report No 2 (BIG-ROP STUDY)., PMID:40473274
EFFICACY AND PROGNOSIS OF ANTI-VEGF AGENTS COMBINED WITH PANRETINAL PHOTOCOAGULATION IN DIABETIC RETINOPATHY: A CLINICAL OBSERVATIONAL STUDY., PMID:40466685
B7-H3 Exacerbates Laser-induced Choroidal Neovascularization by Promoting Macrophage Recruitment and Polarization via S100A8/A9., PMID:40456216
Several Common Genetic Variations Associate With Functional or Anatomic Effects of Anti-VEGF Treatment in Conditions With Macular Edema., PMID:40455044
A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models., PMID:40452841
An Engineered Intravitreal Injection Retinal-Pigment-Epithelium-Tropic Adeno-Associated Virus Vector Expressing a Bispecific Antibody Binding VEGF-A and ANG-2 Rescues Neovascular Age-Related Macular Degeneration in Animal Models and Patients., PMID:40443830
Efficacy and safety of prophylactic simultaneous intravitreal moxifloxacin injection with standard intravitreal anti-VEGF injection procedure in cases of cystoid macular edema and macular neovascularization., PMID:40405143
Anti-CHI3L1 antibody suppresses colon cancer growth through downregulation of VEGFA and NAMPT expression., PMID:40377878
Unveiling the role of oxidative stress in ANCA-associated glomerulonephritis through integrated machine learning and bioinformatics analyses., PMID:40369957
[Biosimilars of ranibizumab in retinal diseases: new possibilities in ophthalmology]., PMID:40353548
Improved functional and morphological outcomes with faricimab in nAMD eyes with poor response to prior intravitreal anti-VEGF therapy., PMID:40338383
Combination therapy with cetirizine and anti-PD-1 antibody suppresses colitis-induced colon tumor formation in mice., PMID:40320111
The role of biological macromolecules in the regulation of angiogenesis in glioblastoma: Focus on vascular growth factors, integrins, and extracellular matrix proteins., PMID:40319984
Potential of autophagy in subretinal fibrosis in neovascular age-related macular degeneration., PMID:40307700
Neuropilin-1: A Multifaceted Target for Cancer Therapy., PMID:40277760
Radiomics Analysis Based on Optical Coherence Tomography to Prognose the Efficacy of Anti-VEGF Therapy of Retinal Vein Occlusion-Related Macular Edema., PMID:40277425
Lymphangiogenesis in the Deepest Invasive Areas of Human Early-Stage Colorectal Cancer., PMID:40243510
Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes., PMID:40217902
[Morphological and functional changes of secondary macular neovascularization in central serous chorioretinopathy under anti-VEGF treatment]., PMID:40199756
Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma., PMID:40180668
Mild antiresorptive activity of an anti-vascular endothelial growth factor A antibody and sunitinib in a rat model of bone resorption., PMID:40177629
Identification and validation of hypoxia-responsive signature pathways in human cardiomyocytes., PMID:40177008
Simultaneous inhibition of fibroblast growth factor-2 and vascular endothelial growth factor-a with RC28-E in diabetic macular edema: a phase 2 randomised trial., PMID:40122579
Long-term nucleus basalis cholinergic lesions alter the structure of cortical vasculature, astrocytic density and microglial activity in Wistar rats., PMID:40121723
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC., PMID:40121197
Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD-1 and VEGF, in Chinese Patients With Advanced Solid Tumors., PMID:40114411
SIRE: Short interval in real life Does intensive anti-VEGF treatment in the first year predict subsequent treatment burden in exudative age-related macular degeneration?, PMID:40114029
Recurrence of neovascular age-related macular degeneration after discontinuation of modified treat and extend treatment., PMID:40089567
Retinal Vascularization Rate Predicts Retinopathy of Prematurity and Remains Unaffected by Low-Dose Bevacizumab Treatment., PMID:40054545
Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial., PMID:40048197
Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial., PMID:40048178
The 1-Step Versus 2-Step Subretinal Injection Trial (1,2-SIT)-A Randomized Controlled Trial to Compare Drug Reflux Following Subretinal Injection., PMID:40020980
Comparing safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in Retinopathy of prematurity., PMID:40016518
Faricimab-Associated Intraocular Inflammation With Features of Herpes Simplex Virus., PMID:40015591
Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer., PMID:40002167
Developing transcriptomic biomarkers for TAVO412 utilizing next generation sequencing analyses of preclinical tumor models., PMID:39995668
Maternal F1 antibodies and cytokines in mother-neonate dog pairs in the Marmota himalayana plague focus., PMID:39991224
Use of a Convolutional Neural Network to Predict the Response of Diabetic Macular Edema to Intravitreal Anti-VEGF Treatment: A Pilot Study., PMID:39986639
DNA Framework-Enabled Ocular Barrier Penetration for Microinvasive Antiangiogenic Therapy., PMID:39979822
Anti-VEGF monotherapy versus anti-VEGF therapy combined with laser or intravitreal glucocorticoid therapy for diabetic macular edema: A Bayesian network meta-analysis., PMID:39973301
Eliminating VEGFA+ tumor-associated neutrophils by antibody-drug conjugates boosts antitumor immunity and potentiates PD-1 immunotherapy in preclinical models of cervical cancer., PMID:39971940
The dual role of VEGF-A in a complex in vitro model of oxaliplatin-induced neurotoxicity: Pain-related and neuroprotective effects., PMID:39939241
Metabolomic Characteristics of Aqueous Humor in Wet Age-Related Macular Degeneration and the Impact of Anti-VEGF Treatment., PMID:39937494
Differential Effects of Retinol-Binding Protein 3 and Anti-VEGF Antibodies on Retinal Dysfunctions in Diabetic Retinopathy., PMID:39937209
Systemic counterregulatory response of angiopoietin-2 after intravitreal injections with faricimab for nAMD., PMID:39920326
A Markov model assessing the cost-effectiveness of various anti-vascular endothelial growth factor drugs and panretinal photocoagulation for the treatment of proliferative diabetic retinopathy., PMID:39910280
Divergent sex-specific pannexin-1 mechanisms in microglia and T cells underlie neuropathic pain., PMID:39892387
From pro-re-nata to fixed-interval regimen: evolving real-world treatment paradigms in anti-VEGF therapy for neovascular AMD., PMID:39881194
For research use only. Not for human or drug use.
